IMMH 010 maleate

CAS No. 2541982-47-0

IMMH 010 maleate( —— )

Catalog No. M37361 CAS No. 2541982-47-0

IMMH 010 maleate (YPD-30 maleate) is an orally available programmed cell death ligand 1 inhibitor with potential antitumor activity for the study of neurological disorders and advanced malignant solid tumors.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 459 In Stock
10MG 657 In Stock
25MG 1026 In Stock
50MG 1386 In Stock
100MG 1832 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    IMMH 010 maleate
  • Note
    Research use only, not for human use.
  • Brief Description
    IMMH 010 maleate (YPD-30 maleate) is an orally available programmed cell death ligand 1 inhibitor with potential antitumor activity for the study of neurological disorders and advanced malignant solid tumors.
  • Description
    IMMH 010 maleate (YPD-30 maleate) is an orally available programmed cell death ligand 1 inhibitor with potential antitumor activity for the study of neurological disorders and advanced malignant solid tumors.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Immunology/Inflammation
  • Target
    PD-1/PD-L1
  • Recptor
    PD-1/PD-L1
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2541982-47-0
  • Formula Weight
    756.04
  • Molecular Formula
    C36H36BrClN2O9
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    C(=C\C(O)=O)\C(O)=O.O(CC=1C=CC=NC1)C2=C(CN[C@H](C(OC(C)C)=O)CO)C=C(Cl)C(OCC3=C(Br)C(=CC=C3)C4=CC=CC=C4)=C2
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • BMS-1166

    BMS-1166 is a?potent PD-1/PD-L1 interaction inhibitor with IC50 of 1.4 nM in a homogenous time-resolved fluorescence binding assay.

  • BMS-1001

    A potent PD-1/PD-L1 interaction inhibitor with IC50 of 2.25 nM in a homogenous time-resolved fluorescence binding assay.

  • Pembrolizumab

    Pertuzumab anti-HER2) a humanized monoclonal antibody and the first in the class of agents called the HER2 dimerization inhibitors impairs the ability of HER2 to bind to other members of the HER family.